Neuroelectrics Raises $17.5 Million To Advance Clinical Trials To Treat Epilepsy & Major Depressive Disorder With A New Platform For Treating Brain Dysfunction

Neuroelectrics, which is developing brain stimulation technologies and therapies, raised $17.5 million a Series A financing led by Morningside Ventures. The funds will be used to further develop Neuroelectrics’ Starstim, non-invasive transcranial electrical stimulation (tES) therapeutic platform and to advance clinical trials in refractory focal epilepsy and at-home treatment of refractory major depressive disorder.

Neuroelectrics’ Starstim platform integrates three key components:

A multi-channel head-piece for brain monitoring and targeted neuromodulation.
Personalized treatment protocols based on extensive neuroscience research, data science, and the user’s own physiological and anatomical data.
A cloud-based system for safe . . .